Page 27 - Boxed Warning News Today

The application to the European Medicines Agency is supported by data from the Phase 3 CARTITUDE-4 study, evaluating the safety and efficacy of cilta-cel in the treatment of patients with relapsed

The application to the European Medicines Agency is supported by data from the Phase 3 CARTITUDE-4 study, evaluating the safety and efficacy of cilta-cel in the treatment of patients with relapsed... | May 25, 2023

The FDA has approved Lexapro (escitalopram) for the treatment of generalized anxiety disorder in pediatric patients 7 years of age and older.

Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE® SALT LAKE CITY, May 24, 2023 -- Myriad Genetics, Inc. , a leader in genetic testing... | June 11, 2023

Brixadi (buprenorphine) is approved for patients with moderate to severe OUD who are already taking or have initiated transmucosal buprenorphine.

24.05.2023 - Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) - Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, ...

Results from phase 2 clinical trial demonstrated EPKINLY (epcoritamab-bysp) delivered 61 percent overall response rate, 38 percent complete response, and 15.6-month median duration of response in

The FDA has approved Rinvoq (upadacitinib) for the treatment of adults with moderately to severely active Crohn disease.

Company Announcement Results from phase 2 clinical trial demonstrated EPKINLY™ delivered 61 percent overall response rate, 38 percent complete response, and 15.6-month median duration of... | May 19, 2023

Treatment with epcoritamab-bysp showed a 61% overall response rate and a 38% complete response rate in heavily pretreated patients with R/R DLBCL.